Statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat,Ĭlick here for more on how to use these ratings. Companies with ratings are not formally covered by a Morningstar analyst, but are Peer companies that do receive analyst-driven ratings.
In order for the stock price to hit the forecast high, the stock would need to plunge -202.49 from its current level, while the stock would need to crash -149.11 from its current level to reach the projected low. Morningstar Quantitative ratings for equities (denoted on this page by ) are generated using an algorithm that compares companies that are not under analyst coverage to Analyst projections state that ATOS is forecast to be at a low of 7.00 and a high of 8.50. Atossa regularly produces informative video content. Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. Atossa’s current focus is on breast cancer and COVID-19. Atossa Therapeutics Inc - ATOS stock news.
#Etos stock code#
Davidson is guided by Morningstar, Inc.'s Code of EthicsĪnd Personal Securities Trading Policy in carrying out his responsibilities. Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Is responsible for overseeing the methodology that supports the quantitative fair value. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., Its value is sinking nearly 21% since the news broke, and 34 million share of ATOS have traded hands, well over the daily average of 21 million.There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate isĪttributed to however, Mr. The average price target represents a 112.46 change from the last price of 3.53. The average price target is 7.50 with a high forecast of 8.00 and a low forecast of 7.00. Indeed, the announcement of the meeting is already precipitating losses for ATOS stock. Based on 2 Wall Street analysts offering 12 month price targets for Atossa Therapeutics in the last 3 months. Regardless of what this could mean for the company’s goings-on, stock dilution is something that most investors are not keen on. ATOS stock surged briefly in 2021 based on several catalysts, but none of them right now is supportive of its current price and valuation. Currently, its operating cash flow stands at a $12.75 million loss. The increase in the supply of common stock would help the company raise funds for operation. Atos provides managed services, consulting and systems integration, Big Data and security, and Worldline (transactional. The company generates over EUR 11 billion in annual revenue (the majority of which is generated in Europe), employs approximately 100,000 staff, and operates in 72 countries. If the amendment sees approval, the total number of common shares of stock will be raised by 100 million. Atos SE is a France-based IT services provider. The special meeting will see ATOS shareholders vote to approve a contentious amendment to the company’s certificate to incorporation. Today, the company announced a shareholder meeting it is setting for early September. Meanwhile, Atossa is looking to offer up significantly more shares on the market. Atos et Siemens accompagnent le Maroc dans la gestion intelligente de son réseau électrique Atos and Siemens to support Morocco in the smart management of its power grid Atos - Monthly information relating to the total number of voting rights and shares making up the. The company continues to conduct its clinical trials abroad.
ATOS Stock Dips Sharply Ahead of Special Meeting